PubRank

Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

Clinical Trial ID NCT00338260

PubWeight™ 50.24‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00338260

Top papers

Rank Title Journal Year PubWeight™‹?›
101 In-treatment stroke volume predicts cardiovascular risk in hypertension. J Hypertens 2011 0.80
102 Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 2008 0.80
103 Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 2000 0.80
104 Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004 0.79
105 Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. Blood Press 2009 0.79
106 Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients. Stroke 2015 0.79
107 Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens 2007 0.79
108 Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). J Hum Hypertens 2004 0.78
109 Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. Am J Hypertens 2001 0.78
110 A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press 2000 0.78
111 Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004 0.78
112 Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005 0.78
113 Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. Am J Hypertens 2008 0.78
114 Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005 0.78
115 Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004 0.77
116 Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. J Hypertens 2000 0.77
117 Maximal exercise capacity is related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am J Hypertens 2001 0.77
118 Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. Blood Press 2002 0.77
119 Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004 0.77
120 Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy. J Hum Hypertens 2004 0.77
121 Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens 2003 0.77
122 Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Am J Cardiol 2007 0.77
123 Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. Am J Hypertens 2005 0.77
124 Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. Eur J Heart Fail 2011 0.77
125 Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. J Hypertens 2008 0.77
126 Blood viscosity, plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy. ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica. Blood Press 2000 0.76
127 Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. J Hypertens 2011 0.76
128 An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther 2003 0.76
129 Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens 2010 0.76
130 Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2002 0.76
131 Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 2004 0.76
132 Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Am Heart J 2004 0.76
133 Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Expert Opin Pharmacother 2004 0.76
134 Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). Am J Cardiol 2005 0.76
135 Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension 2015 0.76
136 Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Press 2006 0.76
137 Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005 0.75
138 Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. Diabet Med 2005 0.75
139 24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy. J Hum Hypertens 2004 0.75
140 The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005 0.75
141 Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. Am J Hypertens 2007 0.75
142 Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. J Hypertens 2014 0.75
143 Influence of non-steady state during isoglycemic hyperinsulinemic clamp in hypertension. A LIFE substudy. Blood Press 1999 0.75
144 Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. Am J Hypertens 2012 0.75
145 The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. J Hum Hypertens 2006 0.75
146 The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium. Blood Press 2012 0.75
147 Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens (Greenwich) 2006 0.75
148 Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. J Hum Hypertens 2004 0.75
149 Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design. Epigenetics 2022 0.75
Next 100